Objective: A number of studies have evaluated the association between flavonoids intake and lung cancer risk. However, results were inconsistent. To clarify the role of flavonoids in lung cancer, we conducted a meta-analysis on this topic. Methods: Two authors independently searched PubMed and EMBASE for studies regarding the association of flavonoids intake with lung cancer risk. Summary relative risks (RRs) with their corresponding 95% confidence intervals (CIs) were calculated by using random-effects model. Results: Eight prospective studies and four case -control studies involving 5073 lung cancer cases and 237 981 non-cases were included in this meta-analysis. The combined results indicated a statistically significant association between highest flavonoids intake and reduced risk of developing lung cancer (RR ¼ 0.76, 95% CI ¼ 0.63 -0.92). Furthermore, an increase in flavonoids intake of 20 mg/day was associated with a 10% decreased risk of developing lung cancer (RR ¼ 0.90, 95% CI ¼ 0.83 -0.97). In stratified analyses, the highest flavonoids intake was significantly associated with decreased lung cancer risk in prospective studies, studies conducted in Finnish population, studies without adjustment for fruits and vegetables or vitamins, males, smokers and studies using dietary history interview for flavonoids intake estimation. Most subclasses of flavonoids were inversely associated with lung cancer except for hesperetin. Conclusions: Our data indicate that high or an increased intake of flavonoids is associated with reduced risk of lung cancer in some population but not in other population.
INTRODUCTION
Lung cancer is one of the leading causes of death in both developed and developing countries (1, 2) . Although incremental improvements are made regularly in the ways in which all treatment modalities including surgery, radiation and medical therapies are applied to patients with lung cancer, the prognosis from this disease has only marginally improved, and the 5-year survival rates have remained under 20% (3). Therefore, efforts toward primary prevention in addition to early detection have come under the spotlight.
Increasing evidence suggests that high fruits and vegetables intake decreases the risk of lung cancer, but it is unclear which bioactive compounds are responsible (4) . Considerable attention has been paid to vitamins such as vitamin A, C and E from fruits and vegetables because of their roles as regulators of cell differentiation or antioxidants (5, 6) . However, recent findings have not demonstrated the expected protective effects of these micronutrients (7, 8) , suggesting that other plant compounds may be responsible for the observation of an inverse association between high fruits and vegetables intake and decreased risk of lung cancer.
Flavonoids are part of a large group of polyphenolic compounds abundant in fruits and vegetables. Previous study by Cao et al. (9) has demonstrated that some flavonoids have much stronger antioxidant activities against peroxyl radicals than vitamin C and E. In addition, a number of epidemiologic studies have reported a protective effect of flavonoids against lung cancer. However, the results were inconsistent. Therefore, we performed a meta-analysis of published epidemiologic studies to derive a precise estimation of the association.
PATIENTS AND METHODS

SEARCH STRATEGY
We performed a literature search in PubMed and EMBASE (last search was updated on 1 January 2009) for all relevant papers using the following keywords 'lung neoplasm', 'lung cancer', 'lung tumor' or 'lung carcinoma' combined with 'flavonoids', 'flavanols', 'flavanones', 'flavones', 'flavonols', 'catechin', 'flavan-3-ols', 'isoflavones' or 'anthocyanidins'. Furthermore, we reviewed the reference lists of retrieved articles to search for more studies. No language restrictions were imposed. Searching was performed in duplicate by two independent authors (N.-P.T and B.Z).
STUDY SELECTION
To be included in our meta-analysis, studies had to fulfill the following criteria. First, they had to be prospective or casecontrol studies. Second, the exposure of interest was flavonoids intake. Third, the outcome of interest was primary lung cancer. Fourth, the study had to enroll unrelated subjects. Last, the relative risk (RR) estimates [or odds ratios (ORs) in case -control studies] with their corresponding 95% confidence intervals (CIs) were reported (or sufficient data to calculate them). If data were duplicated in more than one study, the most recent and complete study was included in the meta-analysis.
DATA EXTRACTION
All data were extracted independently and in duplicate by two authors (N.-P.T and B.Z) who used a standardized data extraction form. The following data were extracted: the first author's last name, year of publication, study design, study population, type of controls for case -control studies ( population-based or hospital-based controls), follow-up time for prospective studies, sample size (cases and controls or prospective cohort size), the exposure of flavonoids intake, the RR or OR estimates with corresponding 95% CIs for each category of flavonoids intake, variables adjusted for in the analysis and estimation method of flavonoids intake. If a study provided several risk estimates, the most completely adjusted estimate was extracted.
STATISTICAL ANALYSIS
The measure of interest was the RR for prospective studies, approximated by the OR in case -control studies, and the corresponding 95% CI. Study-specific risk estimates and 95% CIs for highest versus non/lowest flavonoids intake level were extracted from each study, and log risk estimates were weighted by inverse of their variances to obtain a pooled risk estimate. Studies were combined by using DerSimonian and Laird random-effects model, which considers both within-and between-study variations (10) .
For dose -response analysis, we used the method proposed by Greenland and Longnecker (11) and Orsini et al. (12) to estimate study-specific slopes from the natural logarithm of the RR across categories of flavonoids intake, assigning to each class the dose corresponding to the midpoint of upper and lower boundaries. The highest open-ended category was assumed to have the same amplitude as the preceding category (11) . Because this method requires the risk estimates with their variance estimates for three or more quantitative exposure categories, studies with only two categories were not included in this analysis. In addition, if studies did not provide the number of cases and non-cases in each exposure category, the variance-weighted least square regression models were used to estimate the slopes. Then, we calculated the pooled RR estimates by pooling the study-specific slopes, using the inverse of the corresponding variances as weights.
Statistical heterogeneity among studies was estimated using Q and I 2 statistics (13). To avoid type II errors resulting from low power, statistical significance was defined as P , 0.10 rather than the traditional 0.05 (14) . The causes of heterogeneity were explored through stratified analyses. Publication bias was evaluated through visual inspection of funnel plots, and the Egger weighted regression method with P , 0.10 was considered representative of statistical significance (15) . A sensitivity analysis was also conducted in which one study was removed at a time and the rest analyzed to estimate whether the results could have been affected markedly by a single study. All statistical analyses were performed with Stata (version 9.0; StataCorp, College Station, TX, USA).
RESULTS
The process of study selection was shown in Fig. 1 . We identified 15 potentially relevant studies concerning flavonoids intake and lung cancer (16 -30) . One study (16) was excluded because it did not report data regarding flavonoids intake and lung cancer independently. Two studies (17, 18) were excluded because they did not provide data on lung cancer risk for highest flavonoids intake versus non/lowest flavonoids intake or an increment of 20 mg/day of flavonoids intake. Thus, a total of 12 studies (19 -30) with 8 prospective studies (19 -26 ) and 4 case -control studies (27 -30) regarding the association of flavonoids intake with lung Jpn J Clin Oncol 2009;39 (6) 353 cancer risk were included in our meta-analysis (Table 1) . Among these studies, three were conducted in the Netherlands (16, 19, 20) , three in Finland (22, 24, 26) , four in the USA (23, 25, 29, 30) , one in Spain (27) and one in Uruguay (28). Among case -control studies, two used hospital-based controls (27, 28) and two used populationbased controls (29, 30) . The risk estimates of lung cancer for highest flavonoids intake versus non/lowest flavonoids intake are shown in Fig. 2 and Table 2 . Overall, we found that highest flavonoids intake was statistically significantly associated with reduced risk of lung cancer (RR ¼ 0.76, 95% CI ¼ 0.63 -0.92). Statistically significant heterogeneity was observed among the study results (Q ¼ 28.74, P ¼ 0.002, I
2 ¼ 61.7%). When subgroup analysis was conducted by study design, a statistically significant 27% decreased risk of developing lung cancer was observed among prospective studies (RR ¼ 0.73, 95% CI ¼ 0.57 -0.93), whereas no such effect was observed among case -control studies (RR ¼ 0.83, 95% CI ¼ 0.60 -1.15). Heterogeneity was significantly reduced among case -control
We also examined if study population affected the pooled RR and degree of heterogeneity ( Table 2 ). The pooled RR for studies conducted in Finland was 0.54 (95% CI ¼ 0.40 -0.73). However, no statistically significant association was noted in the USA (RR ¼ 0.95, 95% CI ¼ 0.82 -1.10), the Netherlands (RR ¼ 0.81, 95% CI ¼ 0.55 -1.21) and other populations (RR ¼ 0.67, 95% CI ¼ 0.44 -1.03). The heterogeneity was significantly reduced among these populations (P values for heterogeneity in Finland, the Netherlands, the USA and others were 0.245, 0.764, 0.215 and 0.265, respectively).
We also stratified the various studies by adjustment for fruits and vegetables or vitamins ( 2 ¼ 0.0%) ( Table 2) . We also did a subgroup analysis by smoking status ( Table 2 ). The inverse association between flavonoids intake and lung cancer risk was observed only in smokers (RR ¼ 0.70, 95% CI ¼ 0.51 -0.95), but not among non-smokers (RR ¼ 0.74, 95% CI ¼ 0.26 -2.12). In addition, the data indicated that the heterogeneity across studies was observed regardless of smoking status (smoking:
A subgroup analysis was also performed according to estimation method of flavonoids intake ( Table 2 ). The summary estimate based on the results from four studies using dietary history interview for flavonoids intake estimation showed that flavonoids intake was statistically significantly associated with reduced risk of lung cancer (RR ¼ 0.58, 95% CI ¼ 0.49 -0.70; Q ¼ 1.59, P ¼ 0.662, I 2 ¼ 0.0%). However, no such association was noted based on the results from seven studies using food frequency questionnaire for flavonoids intake estimation (RR ¼ 0.91, 95% CI ¼ 0.79 -1.04; Q ¼ 6.50, P ¼ 0.370, I 2 ¼ 7.7%). We also conducted a subgroup analysis by subclasses of flavonoids (Table 2 ). Most subclasses of flavonoids are inversely associated with lung cancer risk except for hesperetin. In addition, we noted that kaempferol was statistically significantly associated with reduced risk of lung cancer 
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Flavonoids intake and lung cancer risk Given the wide array of measurement categories reported among studies, we also conducted dose -response analysis of flavonoids intake for lung cancer risk (Fig. 3) . Our data indicated that an increase in flavonoids intake of 20 mg/day was statistically significantly associated with a 10% decreased risk of developing lung cancer (RR ¼ 0.90, 95% CI ¼ 0.83 -0.97).
There was no indication of publication bias from either visualization of the funnel plot (Fig. 4) or Egger's test (P ¼ 0.695). A sensitivity analysis which one study was removed at a time was performed to evaluate the stability of the results (Fig. 5) . The summary RR ranged from 0. 
DISCUSSION
This is the first meta-analysis evaluating the potential association between flavonoids intake and lung cancer risk. Eight prospective studies and four case -control studies involving 5073 lung cancer cases and 237 981 non-cases were included in our analysis. Our data suggest that high flavonoids intake have a protective effect against lung cancer. Furthermore, an increase in flavonoids intake of 20 mg/day was statistically significantly associated with a 10% decreased risk of developing lung cancer.
Flavonoids influence several important biological functions, which may explain the observed inverse associations of flavonoids intake with lung cancer risk (31) . In experimental system, the free radical scavenging ability of flavonoids has been fairly well characterized. In addition, in animal models and in vitro system, flavonoids have also been shown to modulate enzymatic activity, induce cell cycle arrest and apoptosis, promote differentiation, regulate host-immune function and inhibit inflammation, cellular proliferation and angiogenesis (31 -33) .
There was statistically significant heterogeneity among the studies on flavonoids intake and lung cancer. When subgroup analysis was conducted by study design, we noted that statistically significant inverse association was only noted among prospective studies but not in case -control studies. It is possible that the negative findings reported from casecontrol studies may have been wrongly estimated, because of recall bias and possibly because early symptoms in patients may have led to a change in dietary habits.
Our data also showed that the association between flavonoids intake and reduced lung cancer risk was more evident among Finland population but not among the USA, the Netherlands or other populations. The different observations may be explained, at least in part, by the variations of flavonoids or subclasses of flavonoids consumption among different countries (34) . In addition, a possible role of ethnic CI, confidence interval; VC, vitamin C; VE, vitamin E; HCC, hospital-based case -control study; OR, odds ratio; PCC, population-based case-control study; RR, relative risk; USA, the United States.
a
We calculated a single OR (95% CI) for total subjects by means of a weighted average of OR (95% CI) for never smokers and OR (95% CI) for ever smokers; BMI, body mass index.
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Flavonoids intake and lung cancer risk differences in genetic backgrounds and the environment they lived in should also be taken into consideration. The subgroup analysis by adjustment for fruits and vegetables or vitamins revealed that the protective effect of flavonoids on lung cancer was significant in studies without adjustment for these factors but not in studies with adjustment for these factors, suggesting that the association between flavonoids and lung cancer might be confounded by the vegetables and vitamins. It remains us that it is important to control the confounding of fruits and vegetables or vitamins intake in future research.
In subgroup analysis by sex, we found that high flavonoids intake was associated with a reduced lung cancer risk among males but not among females, which suggested that gender might be an important modifier of the effects of flavonoids. The reasons for this remain unclear. It is probably because that the protective effect of flavonoids on lung cancer might be masked by the effect of estrogen, which has been suggested to be a potential risk factor for lung cancer (35, 36) .
When subgroup analysis was conducted by smoking status, we found that an inverse association between flavonoids intake and lung cancer risk was stronger among smokers than non-smokers. Smoking has been strongly implicated as a risk factor for lung cancer. Multiple evidences support the major pathological mechanism of oxidative stress linking smoking to lung cancer. Thus, the function of flavonoids as antioxidants may explain the reduction of lung cancer risk seen in smokers.
In the subgroup analysis by estimation method of flavonoids intake, we also found that flavonoids intake was statistically significantly associated with decreased lung cancer risk among studies using dietary history interview for flavonoids intake estimation but not among studies using food frequency questionnaire for flavonoids intake estimation. The different observation can be a consequence of response bias due to different assessment techniques or to chance alone. We also stratified studies by subclasses of flavonoids, since flavonoids contain many types of chemicals with various type of biological activity. Our data indicated that most subclasses of flavonoids were inversely associated with lung cancer risk except for hesperetin. Our results were consistent with the findings by Cui et al. (30) which suggested that high intake or an increased intake of hesperetin was positively associated with lung cancer risk (30 versus ,10 mg/day: OR ¼ 1.6, 95% CI ¼ 1.1 -2.2; an increase intake of 80 mg/day: OR ¼ 1.7, 95% CI ¼ 1.0-2.9, P trend ¼ 0.044). The estimated effect differences between hesperetin and other flavonoid compounds may have been caused by differences in their chemical structure, bioavailability, distribution and metabolism (37) . Considerable differences in antioxidative effect between hesperetin and other flavonoid compounds have also been demonstrated in vitro studies (37) . In addition, it is also likely that the results in the subgroup analysis may be due to chance because only two studies were included in the analysis.
Several studies also estimated the potential effect of flavonoids intake on subtypes of lung cancer, since the subtypes of lung cancer are etiologically and histologically clearly distinct (22) . However, the results were inconsistent (28, 29) . In this meta-analysis, the number of studies on the association of flavonoids intake with subtypes of lung cancer was relatively small. Therefore, we could not draw a conclusion.
Several limitations should be taken into account when interpreting the results in our study. First, as in all observational studies, the possibility of bias and confounding can not be excluded. However, prospective studies, which are less susceptible to bias because of the prospective design, also showed a statistically significant inverse association between flavonoids intake and lung cancer, suggesting that the finding is not likely attributable to recall and selection bias. Second, only published studies were included in our meta-analysis. Therefore, publication bias may have occurred, although no publication bias was indicated from both visualization of the funnel plot and Egger's test. Finally, studies included in our meta-analysis were mainly conducted in Finland, the Netherlands, the USA, Spain and 
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Flavonoids intake and lung cancer risk Uruguay; therefore, the data should be extrapolated to other populations with caution.
In conclusion, our results based on eight prospective studies and four case -control studies suggest that flavonoids intake have a protective effect on the risk of developing lung cancer in some population but not in other population. Given the relative paucity of human data, prospective cohort studies with larger sample size, well-controlled confounding factors, more accurate measurement of flavonoids intake and longer duration of follow-up are needed to affirm the protective effect of flavonoids on lung cancer.
Funding
